Testing for a germline SUFU mutations should be proposed in all patients presenting with a tumour belonging to SUFU spectrum (SHH-MB, BCC, meningioma, ovarian stromal or fibrous tumour) and for whom genetic predisposition is suspected because of young age at diagnosis, a familial history of cancer of multiple tumours. This evidence concerns the gene SUFU and fibroblastic neoplasm.